Stock News

 

Sign Up For Our
FREE Newsletter


Timely Market Commentary
Daily Stock Picks
News Analysis

Email Address: * Required

Country:
Zipcode:

 
 

April 30, 2010

Nine of Alfred Hitchcock’s Films are Restored; 30 Years Since His Death

Filed under: World News — Tags: , , , , — The Editor @ 8:55 pm

crwe-newswire

Las Vegas, NV (CRWE NEWSWIRE - WORLD NEWS)

At least nine of Alfred Hitchcock’s rare silent films, made at the beginning of his career, will be staged in 2012 in many public screenings, The Independent has reported.

These forgotten silent films made by a young Hitchcock are said to feature elements that characterize his later Hollywood works. These footages are going to be released in 2012 and expected to be aired as part of the Cultural Olympiad, although it still needs to be officially confirmed.

Robin Baker, the British Film Institute’s head curator, calls Hitchcock’s silent movie The Mountain Eagle the “holy grail” of lost British films. “It was made in 1926 and was his last silent film featuring a sexually vulnerable young woman and a case of miscarriage of justice,” he said to The Independent.

Three of Hitchcock’s restored silent films are The Pleasure Garden (1925), The Lodger (1927) and The Farmer’s Wife (1928).

30 years since his death

Thursday marked the 30th anniversary since Alfred Hitchcock’s death. Hitchcock was an English filmmaker and producer, who produced several films in a career of sixty years.

Hitchcock was born in Leytonstone, London, United Kingdom on August 13, 1899. He described his childhood as being very lonely and sheltered, a situation aggravated by his obesity. His father died when he was 14. After he graduated, he became intrigued by photography and started working in film production in London on a branch of what would become Paramount Pictures. After a successful career with silent movies and the early talkie ones in the United Kingdom, in March 1939, David O. Selznick signed Hitchcock onto a seven-year contract beginning in March 1939 as the Hitchcock family was moving to Hollywood, United States. He was nominated for five Academy Awards as a best director but never took home the prize, and one of his most succesful movies during his Hollywood stay was the 1958 film Vertigo, featuring James Stewart and Kim Novak. Hitchcock became a United States citizen in 1956 while retaining his British citizenship.

Hitchcock’s last successful production was the 1972 film Frenzy. The 1976 film Family Plot was his last film. Hitchcock died from kidney failure in his home at Bel Air, Los Angeles, California, at 80. His body was cremated and his ashes were thrown in the Pacific Ocean.

 

 

 

********************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWENewswire.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWENewswire.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more) Rule 17B requires disclosure of payment for investor relations.

 
 
 
 

Cyclacel Receives Complaint Filed by Celgene Seeking to Avoid Certain Cyclacel Patents

crwe-newswire

BERKELEY HEIGHTS, N.J., April 30, 2010 (CRWE NEWSWIRE) - Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC - News) (Nasdaq:CYCCP - News), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that it received a complaint filed by Celgene Corporation seeking a declaration from the court that four Cyclacel-owned patents, which claim the use of romidepsin injection in T-cell lymphomas, are not infringed by Celgene’s products and are invalid. Cyclacel and its counsel have not had an opportunity to thoroughly review these filings.

The four patents cited in the complaint do not involve Cyclacel’s clinical development candidates nor its commercial products.

About Cyclacel Pharmaceuticals, Inc.

Cyclacel is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders. Three product candidates are in clinical development: Sapacitabine (CYC682), a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and lung cancer. Seliciclib (CYC202 or R-roscovitine), a CDK (cyclin dependent kinase) inhibitor, is in Phase 2 studies for the treatment of lung cancer and nasopharyngeal cancer and in a Phase 1 trial in combination with sapacitabine. CYC116, an Aurora kinase and VEGFR2 inhibitor, is in a Phase 1 trial in patients with solid tumors. Cyclacel’s ALIGN Pharmaceuticals subsidiary markets directly in the U.S. Xclair(R) Cream for radiation dermatitis, Numoisyn(R) Liquid and Numoisyn(R) Lozenges for xerostomia. Cyclacel’s strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a portfolio of commercial products and a development pipeline of novel drug candidates. Please visit www.cyclacel.com for additional information.

Forward-looking Statements

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety, and intended utilization of Cyclacel’s product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, the risk that Cyclacel will not obtain approval to market its products, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “forecast,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic and current filings that have been filed with the Securities and Exchange Commission and are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

(C) Copyright 2010 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel(R) are trademarks of Cyclacel Pharmaceuticals, Inc. Numoisyn(R) and Xclair(R) are trademarks of Sinclair Pharma plc.

Contact:

Cyclacel Pharmaceuticals, Inc.
Investors/Media:
Corey Sohmer
(908) 517-7330
csohmer@cyclacel.com

 

 

 

******************************************************************

 

CRWENewswire tracks and announces stocks daily and is pleased to offer its Stock Alerts. Investors can receive FREE Stock Alerts by visiting http://www.crwenewswire.com/signup

About CRWENewswire.com

CRWENewswire.com is an independent electronic informative online financial news publication company dedicated in providing company associates, business and financial professionals with economic and investment information, as well as stock highlights. CRWENewswire.com is a division of Crown Equity Holdings, Inc.

CRWENewswire.com is not a registered investment advisor or broker-dealer. CRWENewswire.com and Crown Equity Holdings, Inc., (CRWE) affiliates, officers, directors, contractors and employees, including may buy and sell additional shares in any company mentioned herein and may profit in the event those shares rise in value. Please do your own Due Diligence before investing in any of the stocks mentioned above.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Release of Liability: Through use of this website viewing or using, you agree to hold CRWENewswire.com, and/or Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur.

Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. (read more) Rule 17B requires disclosure of payment for investor relations.

 

Integral Systems Announces CFO Transition

crwe-newswire

COLUMBIA, Md., April 30, 2010 (CRWE NEWSWIRE) - Integral Systems, Inc. (Nasdaq:ISYS - News), today announced that Bill Bambarger has announced his intention to resign as Chief Financial Officer of Integral Systems, citing personal and health reasons. Mr. Bambarger will remain in his role to assist the Company in the transition process until July 31, 2010. The Company has commenced a search for a new CFO.

Paul Casner, President and CEO of Integral Systems said, “Bill has made a valuable contribution to Integral Systems during his three years with our Company. He led the transformation of Integral Systems’ financial infrastructure and governance and built a professional finance and accounting organization. We look forward to Bill’s on-going contribution through the transition process and wish him the best of luck in his personal and professional endeavors.”

About Integral Systems

Integral Systems, Inc., of Columbia, MD, applies more than 25 years experience to provide integrated technology solutions for satellite communications-interfaced systems. Customers have relied on the Integral Systems family of companies (Integral Systems, Inc., Integral Systems Europe, Lumistar, Inc., Newpoint Technologies, Inc., RT Logic, and SAT Corporation) to deliver on time and on budget for more than 250 satellite missions. Our dedication to customer service has solidified long-term relationships with the U.S. Air Force, NASA, NOAA, and nearly every satellite operator in the world. Integral Systems was named the Region III Prime Contractor of the Year by the U.S. Small Business Administration in 2009. For more information, visit www.integ.com.

Contact:

Integral Systems, Inc.
Andrew Miller, Vice President, External Communications
443.539.5124
amiller@integ.com

 

 

 

******************************************************************

 

CRWENewswire tracks and announces stocks daily and is pleased to offer its Stock Alerts. Investors can receive FREE Stock Alerts by visiting http://www.crwenewswire.com/signup

About CRWENewswire.com

CRWENewswire.com is an independent electronic informative online financial news publication company dedicated in providing company associates, business and financial professionals with economic and investment information, as well as stock highlights. CRWENewswire.com is a division of Crown Equity Holdings, Inc.

CRWENewswire.com is not a registered investment advisor or broker-dealer. CRWENewswire.com and Crown Equity Holdings, Inc., (CRWE) affiliates, officers, directors, contractors and employees, including may buy and sell additional shares in any company mentioned herein and may profit in the event those shares rise in value. Please do your own Due Diligence before investing in any of the stocks mentioned above.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Release of Liability: Through use of this website viewing or using, you agree to hold CRWENewswire.com, and/or Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur.

Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. (read more) Rule 17B requires disclosure of payment for investor relations.

 

OMNI Announces 1st Quarter 2010 Earnings Conference Call Information

crwe-newswire

CARENCRO, La., April 30, 2010 (CRWE NEWSWIRE) - OMNI Energy Services Corp. (the “Company” or “OMNI”) today announced plans to release financial results for the quarter ended March 31, 2010, on Wednesday, May 5, 2010 after the close of the markets in the United States. The Company will conduct a conference call at 2:00 P.M. CDT on Thursday, May 6, 2010, to discuss the results with analysts, investors and other interested parties. Individuals who wish to participate in the conference call should dial (877) 303-7550, confirmation code 73034839, in the United States or (760) 666-3601, confirmation code 73034839, from outside the United States.

Listeners may also connect to the simultaneous webcast available from the investor relations section of the Company’s web site at www.omnienergy.com. A replay of the webcast will be available at this site for 30 days after the call.

Date: May 6, 2010
Time: 2:00 PM CT

Listen via Internet: http://ir.omnienergy.com/

Schedule this webcast into MS-Outlook calendar (click open when prompted):http://apps.shareholder.com/PNWOutlook/t.aspx?m=42364&k=6E135710

 

Toll-free: (877) 303-7550
International: (760) 666-3601
Password: 73034839

Headquartered in Carencro, LA, OMNI Energy Services Corp. offers a broad range of integrated services to geophysical companies engaged in the acquisition of on-shore seismic data and to oil and gas companies operating primarily in the Gulf of Mexico. OMNI provides its services through three business segments: Seismic Drilling (including drilling, survey and permitting services), Environmental and Other Services, and Equipment Leasing. OMNI’s services play a significant role with geophysical companies who have operations in marsh, swamp, shallow water and the U.S. Gulf Coast also called transition zones and contiguous dry land areas also called highland zones.

Forward-looking statements in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that all forward-looking statements involve risks and uncertainties associated with the impact of the current economic climate, the efficacy of I.M.P.A.C.T. ™ cleaning technology and receipt of its patent, the timely conversion of seismic drilling backlog into revenue, the acceptance and use of OMNI’s environmental cleaning services, OMNI’s dependence on activity in the oil and gas industry, labor shortages, permit delays, dependence on significant customers, seasonality and weather risks, competition, technological evolution, the ultimate outcome of pending litigation, the continued growth of our environmental and other services and equipment leasing business segments, and other risks detailed in OMNI’s filings with the Securities and Exchange Commission.

OMNI&

Contact:

OMNI Energy Services Corp.
Ronald D. Mogel, Senior Vice President and
Chief Financial Officer
(337) 896-6664

 

 

 

******************************************************************

 

CRWENewswire tracks and announces stocks daily and is pleased to offer its Stock Alerts. Investors can receive FREE Stock Alerts by visiting http://www.crwenewswire.com/signup

About CRWENewswire.com

CRWENewswire.com is an independent electronic informative online financial news publication company dedicated in providing company associates, business and financial professionals with economic and investment information, as well as stock highlights. CRWENewswire.com is a division of Crown Equity Holdings, Inc.

CRWENewswire.com is not a registered investment advisor or broker-dealer. CRWENewswire.com and Crown Equity Holdings, Inc., (CRWE) affiliates, officers, directors, contractors and employees, including may buy and sell additional shares in any company mentioned herein and may profit in the event those shares rise in value. Please do your own Due Diligence before investing in any of the stocks mentioned above.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Release of Liability: Through use of this website viewing or using, you agree to hold CRWENewswire.com, and/or Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur.

Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. (read more) Rule 17B requires disclosure of payment for investor relations.

 

Compassionate Therapeutic Solutions, LLC Introduces the Wellness Center to Cancer Patients

crwe-newswire

COLORADO SPRINGS, Colo., - April 30, 2010 (CRWE NEWSWIRE) - GT Legend Automotive Holdings, Inc. (Pink Sheets:GTLA - News) in conjunction with Compassionate Therapeutic Solutions, LLC, announced today that Eugene Espinosa, the company’s President, has been busy promoting the CTS wellness center via a series of presentations to cancer patients in Colorado Springs and the surrounding communities.

The National Cancer Institute (NCI) is 1 of 27 Institutes and Centers that comprise the U.S. National Institutes of Health (NIH) and is a component of the U.S. Department of Health and Human Services. In the National Cancer Institute Act of 1937, NCI was established as the Nation’s principal agency for cancer research. As a Federal Government agency, NCI receives its funds from the U.S. Congress. These funds support research at the Institute’s headquarters in Bethesda, Maryland, and in laboratories and medical centers throughout the United States and in other countries. NCI’s budget for the 2008 fiscal year was $4.83 billion. For the 2007 fiscal year, it was $4.79 billion, and, for 2006, it was $4.75 billion. (Source: www.cancer.gov).

According to the American Cancer Society’s 2003 data, more than 1,300,000 Americans are diagnosed with cancer each year. At least 300,000 of them will undergo chemotherapy, and 132,000 patients may have therapeutic cannabis recommended to them to combat the side effects of conventional treatments (Source: www.americansforsafeaccess.org). Vinciguerra et al. found that 78% of 56 patients suffering from nausea who were resistant to standard drugs became symptom-free after inhaling cannabis (Source: www.concept420.com).

A 1999 report published by the Institutes of Medicine stated that nausea, appetite loss, pain and anxiety, all of which are symptoms associated with cancer, can be mitigated by medical marijuana. The same report also stated that pills are generally ineffective in treating patients experiencing severe nausea or vomiting because of the difficulty in swallowing or keeping a pill down and the slow onset of the drug effect. Therefore, they conclude that cannabinoid inhalation is effective in treating the nausea that is caused by chemotherapy.

Kathryn Newman, R.N., M.S., states, “Medical marijuana can be used as a pain reliever to combat the discomfort caused by various cancers. It can also soothe the nausea associated with chemotherapy. In addition to pain relief, studies also show that the euphoric effects of the chemical THC which is contained in cannabis may act as a mood elevator; this is yet another benefit for cancer patients.”

About Compassionate Therapeutic Solutions, LLC: Compassionate Therapeutic Solutions, LLC is a multidisciplinary behavioral health care practice that offers mental health, substance abuse and primary caregiver services to communities of Colorado. The company’s focus is to provide cost-effective quality treatment and to create, promote, and maintain a positive customer relationship with clients, associates and the community. One of the functions of the clinic is to provide comprehensive care to individuals who are registered and authorized to utilize medical marijuana.

Forward Looking Statements:

This press release contains certain forward-looking statements. Investors are cautioned that certain statements in this release are “forward looking statements” and involve both known and unknown risks, uncertainties and other factors. Such uncertainties include, among others, certain risks associated with the operation of the company described above. The Company’s actual results could differ materially from expected results.

Contact:

Orion Financial
Brokers & Analysts
800-400-1290

 

 

******************************************************************

 

CRWENewswire tracks and announces stocks daily and is pleased to offer its Stock Alerts. Investors can receive FREE Stock Alerts by visiting http://www.crwenewswire.com/signup

About CRWENewswire.com

CRWENewswire.com is an independent electronic informative online financial news publication company dedicated in providing company associates, business and financial professionals with economic and investment information, as well as stock highlights. CRWENewswire.com is a division of Crown Equity Holdings, Inc.

CRWENewswire.com is not a registered investment advisor or broker-dealer. CRWENewswire.com and Crown Equity Holdings, Inc., (CRWE) affiliates, officers, directors, contractors and employees, including may buy and sell additional shares in any company mentioned herein and may profit in the event those shares rise in value. Please do your own Due Diligence before investing in any of the stocks mentioned above.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Release of Liability: Through use of this website viewing or using, you agree to hold CRWENewswire.com, and/or Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur.

Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. (read more) Rule 17B requires disclosure of payment for investor relations.

 
Older Posts »
 
 

Powered by WordPress

crownequityholdings.com |  pennyotcstock.com |  crowntradingsystems.com |  crwenews.com |  crwenewswire.com |  crwefinance.com |  crown.dynastycouncil.org |  doubleinstocks.com |  crwedomains.com |  crwenews.net |  crownpartnersinc.com |  stock-ir.com |  drstockpick.com |  crwewallstreet.com |  crownbazar.com |  crownbeautymall.com |  dynastycouncil.info |  dynastycouncil.net |  dynastycouncil.org |  crwefinance.com |  stockhottips.com |  stock-pr.com |  pennyomega.com |  doctorstockpick.com |  bestotc.com |  crwepicks.com |  crweselect.com |  pennygovernance.com